Results 61 to 70 of about 8,768 (188)

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial

Pediatrics and Neonatology
Background: Persistent Pulmonary Hypertension of the newborn (PPHN) is characterized by sustained elevated Pulmonary Artery Pressure (PAP). Drug resistance and the adverse effects of current therapeutic agents warrant investigation of other targeted ...
Mandana Kashaki, Arash Mohazzab, Mohammad Radgoudarzi, Arash Bordbar, Sama Dabbagh   +4 more
doaj   +1 more source

Endothelial Dysfunction in Systemic Sclerosis: The Passive Leg Movement Technique in the Assessment of Nitric Oxide–Mediated Vascular Impairment

ACR Open Rheumatology, Volume 8, Issue 4, April 2026.
Objective To evaluate the impairment of nitric oxide (NO)–mediated vascular function in patients with systemic sclerosis (SSc) compared with healthy controls through passive leg movement (PLM), which is a noninvasive technique largely dependent on NO bioavailability. Methods Twenty‐one patients with SSc and 21 age‐ and sex‐matched healthy controls were
Silvia Guella, Giovanni Baldassarre, Alessandro Gratton, Lucrezia Zuccarelli, Elena Treppo, Emma Di Poi, Bruno Grassi, Luca Quartuccio   +7 more
wiley   +1 more source

Influence of hydroxybosentan on determination of bosentan in human plasma

, 2015
Bosentan is a drug used in the treatment of pulmonary arterial hypertension. Evaluation of bosentan pharmacokinetics is an important step of the drug development.
Izabela Domel, Piotr J. Rudzki, Katarzyna Buś - Kwaśnik, Edyta Gilant, Michał Kaza   +4 more
core   +1 more source

Effect of Once‐Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants

The Journal of Clinical Pharmacology, Volume 66, Issue 4, April 2026.
Abstract Macitentan is an oral, dual ETA/ETB endothelin receptor antagonist, currently approved in adults for the treatment of pulmonary arterial hypertension (PAH) at a once‐daily dose of 10 mg. Pre‐clinical and clinical data suggest that greater ETB receptor inhibition may result in greater efficacy.
Dénes Csonka, Cynthia Gargano, Navin Goyal, Marc De Meulder, Vitaly Yartsev, Juan Jose Perez Ruixo   +5 more
wiley   +1 more source

Bosentan for the treatment of adult pulmonary hypertension

, 2011
Pulmonary hypertension is a severe progressive disease with a marked morbidity and a high mortality attributed to right heart failure. Bosentan, a dual endothelin receptor antagonist, is an effective and well-tolerated oral therapy for the management of
David Kilpatrick, Nathan Dwyer
core   +2 more sources

Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers

Scientific Reports
Bosentan is a drug used to treat pulmonary hypertension via dual endothelial receptor antagonism. Bosentan has a restricted oral bioavailability, a problem that's mostly due to poor solubility and hepatic metabolism.
Rania Mohamed Sakr, Abdelaziz El Sayed Abdelaziz, Eman Ahmed Mazyed, Gamal Mohamed El Maghraby   +3 more
doaj   +1 more source

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Canadian Respiratory Journal, 2018
Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH).
Su-Gang Gong, Lan Wang, Bigyan Pudasaini, Ping Yuan, Rong Jiang, Qin-Hua Zhao, Jing He, Rui Zhang, Wen-hui Wu, Jin-Ming Liu, Cai-cun Zhou   +10 more
doaj   +1 more source

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children

Pulmonary Circulation, Volume 16, Issue 2, June 2026.
ABSTRACT Use of subcutaneous treprostinil (TRE) in children with pulmonary hypertension (PH) secondary to lung disease (group 3 PH) is not well described. We hypothesized that initiation of TRE is associated with improvement in PH severity and right ventricular (RV) function with minimal early side effects.
Kaushik Parvathaneni, Justin J. Kochanski, Megha D. Tandel, Esther Liu, Alisa Arunamata, Jeffrey A. Feinstein, Rachel K. Hopper   +6 more
wiley   +1 more source

Challenges and Strategies in Managing Pulmonary Arterial Hypertension Within the Indian Healthcare System: A Consensus Statement From the Pulmonary Vascular Research Institute India Taskforce

Pulmonary Circulation, Volume 16, Issue 2, June 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) in India is a substantial yet under‐recognized contributor to cardiovascular morbidity and mortality. Its progressive course, nonspecific early manifestations, and heterogeneous aetiologies often lead to delayed diagnosis and fragmented care.
Prashant Bobhate, Neeraj Awasthy, Abraham Samuel Babu, Shatabdi Giri, Arun Gopalakrishnan, Sivadasanpillai Harikrishnan, Niharikar Karandikar, Basha J. Khan, Snehal Kulkarni, Shine Kumar, Rahul Mehrotra, Smrutiranjan Mohanty, S. Ramakrishnan, Anita Saxena, Padmanabha Shenoy, B. K. Srinivasa Sastry, T. Sunder   +16 more
wiley   +1 more source

Successful Treatment with Bosentan for Pulmonary Hypertension and Reduced Peripheral Circulation in Juvenile Systemic Sclerosis

, 2011
Pulmonary arterial hypertension (PAH) when associated with systemic sclerosis (SSc) (SSc-PAH) is one of the leading causes of mortality and is found in 10-15% of adult patients with SSc.
Shimizu, Masaki, Takehara, Kazuhiko, 40613964, 30525035, Hashida, Yoko, 50142253, 22275, Yokoyama, Tadafumi, 1183, 20436, 143, Ohta, Kunio, 300, 00303280, 467, 22272, 40210281, 22273, 22274, 10401902, Saito, Takekatsu, Yachie, Akihiro, Nakayama, Yuko, Ueno, Kazuyuki   +23 more
core   +1 more source